ZARR

News and price dashboard

Swept 14:18
Sources
27, all reachable
Items
31729
Flagged
3616
Last swept
14:18

Sources

All 27 enabled. Mute or unmute any of them.

Show stories from muted sources

STOCKS

66

OPTIONS

21

COMING UP

US majors and your names' earnings, next 7 days

Full calendar

Everything else — unscored, browse only, never pushed

Brief

Two biotech readouts dominate the feed

The two biggest moves in this feed are both biotech and both company-specific. Alector jumped 55.2% in pre-open trading after licensing AL050, its brain-penetrant GCase enzyme replacement therapy for Parkinson's, exclusively and globally to Genentech. Alector gets $100 million upfront, up to $1.17 billion in development, regulatory and commercial milestones, and tiered royalties, and keeps full ownership of its Alector Brain Carrier blood-brain-barrier platform for all non-GCase programs. CEO Arnon Rosenthal said the deal pushes the cash runway into 2029, against prior guidance of 2027. The stock was trading at $2.81 versus a 52-week high of $3.40. Vaxcyte rose 51.3% pre-open on topline data from OPUS-1, the pivotal adult Phase 3 of its 31-valent pneumococcal conjugate VAX-31. The trial enrolled 4,047 participants across roughly 30 US sites and hit all co-primary immunogenicity endpoints: all 28 serotypes shared with Pfizer's Prevnar 20 and Merck's Capvaxive cleared noninferiority, and the three VAX-31-unique serotypes plus cross-reactive 20B showed superiority. Guggenheim lifted its target to $125 from $116 with a Buy; the article also notes short interest around 10% of float going into the readout. OPUS-2 and OPUS-3 are due in the first half of 2027, with a BLA targeted for the first half of 2028.

CH Robinson buys RXO, acquirer discount

CH Robinson fell 7.4% pre-open after agreeing to acquire RXO in a stock-and-cash deal worth roughly $5.8 billion, creating a combined logistics business valued above $25 billion. RXO holders get $17.25 in cash plus 0.0856 CHRW shares per share, a 27% premium to RXO's 90-day VWAP. About 43% of the consideration is CHRW stock, which dilutes existing holders, with the cash side funded by new debt under a Morgan Stanley bridge facility. Buybacks are paused until net debt to adjusted EBITDA returns to the 1.75x–2.25x target range, expected by end-2028. Management projects adjusted EPS accretion within nine months of closing and mid-teens accretion by 2028, contingent on $300 million of net run-rate cost synergies. Wells Fargo reiterated Buy. A separate headline-only item notes RXO shares soaring on the same announcement, and the article's own ticker strip showed RXO up 9.46% and CHRW up 2.99% intraday.

Intel slides on Terafab competition

Intel fell 4.2% pre-open after reports that TSMC is in preliminary talks with Elon Musk's Terafab venture about a manufacturing partnership at the planned Texas semiconductor site, where Intel had been the only publicly named partner. The story broke in an industry newsletter on October 2 and Musk confirmed it on social media on October 3. The article adds analyst commentary on continued Intel data-center share loss to AMD, and notes the stock had run from a 52-week low of $32.89 to a high of $142.35, opening at $124.01 and sliding to $114.33, leaving it exposed to profit-taking.

Autodesk lifted by the Schneider-PTC deal

Autodesk rose 3.8% pre-open after Schneider Electric agreed to buy PTC for $22.6 billion all cash, a 42.3% premium to PTC's last close and Schneider's largest acquisition ever. Investors re-rated Autodesk as a comparable engineering software asset. The piece also cites Autodesk's own recent news: Autodesk Assistant going generally available across Fusion at Autodesk University 2026, extending agentic AI to Inventor, Moldflow and Vault, with Flex token access for AI workflows starting October 6, plus a deepened AI collaboration with Arcadis. Autodesk's most recent quarter showed 16% revenue growth and a 57% rise in net income.

Vistra, DraftKings and Harley on policy and upgrades

Vistra rose 4.5% pre-open on reports the federal government is preparing a roughly $4 billion loan package for capacity upgrades at three of its nuclear plants, two in Ohio and one in Pennsylvania, with Energy Secretary Chris Wright expected to announce it at the Perry complex near Cleveland. The article frames it against the administration's goal of quadrupling US nuclear capacity to 400 gigawatts by 2050, and cites Siebert Williams Shank initiating at Buy with a $202 target and Bernstein at Outperform with $181. DraftKings rallied nearly 4.8% pre-open after BofA upgraded it from Neutral to Buy with a $27 target, arguing prediction markets are a win-win growth avenue, cannibalisation risk is lower than feared, consensus estimates are bottoming and risk-reward has turned favourable; UBS kept Buy with a $48 target. The stock had been just above its 52-week low of $18.52, down roughly 47% over twelve months. Harley-Davidson gained 3.8% pre-open on a Citi upgrade to Buy with the target raised to $33 from $31, citing improving retail momentum and a major 2027 product launch, alongside more than $1.3 million of net insider buying and a Q2 beat with raised full-year guidance on retail units and operating income.

Trevi takeover battle escalates

Trevi Finanziaria rose 5.7% to €5.15 after Webuild agreed to buy about 9.1 million shares, roughly 13.9% of capital, from Praude Asset Management and affiliated funds at €5.165 a share, about €47.1 million, settling October 7 and taking Webuild to roughly 18.91%. That price supersedes Webuild's prior €4.50 cash offer, an uplift of about 14.8%, and follows Friday's cut in the minimum acceptance threshold from 66.7% to 50% plus one. Alantra kept a Hold but said the move raises the bar for rival bidder ICOP, whose share-exchange offer still needs 66% acceptance and now implies a discount; Trevi's board declared ICOP's revised price non-congruous.

Semi and other analyst notes read in full

Cantor Fitzgerald kept Overweight on Nvidia with a $350 target after a non-deal roadshow, saying consensus is too low and expecting another strong growth year into 2028; the stock was $233.95 with 83% trailing revenue growth. The same firm kept Overweight and $700 on AMD at $633.91, flagging Q4 guidance implying higher-than-expected Helios shipments as a possible catalyst, though more a first-half 2027 story, and said it prefers Micron in memory on HBM share. Wedbush started Korsana Biosciences at Outperform with a $44 target against a $30.49 price, on next-generation anti-amyloid KRSA-028 and its brain shuttle delivery; it models an earliest launch in FY2033 and FY2035 revenue of $1.192 billion, with Phase 1 SAD data mid-2027 and MAD data around end-2027 or Q1 2028, and notes roughly $9 a share in cash. BofA began NKT at Buy with a DKK 1,100 target, 23% above the DKK 893 cited, calling it one of only three suppliers able to meet HVDC cable demand; it sees free cash flow going from minus €127 million in 2026 to €211 million in 2028, group EBITDA margin rising from 10.9% in 2025 to 17% in 2030, and a €13 billion high-voltage backlog at end-Q2 2026, roughly 70% interconnectors and 30% offshore wind.

The headline-only analyst pile

The bulk of the remaining feed is a long run of sell-side headlines with no text behind them. H.C. Wainwright alone accounts for reiterations on Cognition Therapeutics ahead of an FDA meeting, Orchestra BioMed on trial enrolment, CervoMed on a new formulation, Alumis on TYK2 data, Monte Rosa on trial data, Vanda after a sleep disorder trial, SpyGlass Pharma, Verastem and Generate Biomedicines. BofA headlines cluster on financials and fintech: target raises on Robinhood, Coinbase and Raymond James, cuts on eToro and Figure Technology, plus an initiation on Vylor at Buy, which pairs with Oppenheimer cutting Corteva to $17 after the Vylor spinoff. Other one-liners include Goldman naming three tactical chip stocks ahead of earnings, Goldman upgrading Komatsu and initiating Richemont at Buy, Melius upgrading Microsoft, Mizuho on Navan and IonQ, TD Cowen initiating Maravai, Northland cutting T1 Energy, Raymond James on B2Gold and Suncor, Canaccord on Niagen, and Cantor on Cloudflare, MongoDB and Beta Technologies. Nasdaq's mechanical "reaches analyst target price" items cover MaxLinear, Avnet, Arrow Electronics, ACLS and VECO.

Corporate one-liners and macro chatter

A steady stream of small corporate headlines with no detail attached: Curaleaf raising its Aurora Cannabis bid to $5 a share, Advanced Drainage Systems buying StormTrap for $530 million, Harrow completing a $30 million purchase of TYRVAYA, Leidos closing its screening JV with Altaris, Nutrien permanently closing its Trinidad nitrogen plant, Baker Hughes signing Venezuela infrastructure deals, Applied Optoelectronics completing a $588 million equity offering, Insmed's CFO stepping down on October 30, and a scattering of small-cap biotech and financing notices. On macro and geopolitics, the X feed carries Yemeni government forces claiming control of Bab el-Mandeb and Dhubab airport, an IRGC warning to a tanker 11 nautical miles north of Khasab in the Strait of Hormuz, the Brazilian real strengthening more than 4% after Bolsonaro beat expectations in the presidential vote, Trump promising $5,000 payments if Republicans win both chambers, and tech billionaires adding a record $845 billion through September. Strategy reported a $21 billion Q3 gain on digital assets, bought 334 BTC for $28.7 million at an average $85,839 and holds 848,000 BTC. OilPrice headlines note South Korea planning to triple Canadian crude imports and Japan ruling out further reserve releases after G7 pledged 100 million barrels.

TradingView noise

Roughly a third of the list is individual TradingView chart posts on gold, EUR/USD, BTC, GBP pairs and assorted altcoins. The two read in full are representative: one calling EUR/AUD higher on a triple bottom and bullish flag, one calling EUR/USD lower after a trendline break. These are retail chart opinions with no news content and nothing to extract.

17 read in full, 200 items in the section

Feed

170 storiesCross-publisher stories only